| Emerging patterns of somatic mutations in cancer IR Watson, K Takahashi, PA Futreal, L Chin Nature Reviews Genetics 14 (10), 703-718, 2013 | 590 | 2013 |
| Cancer therapy shapes the fitness landscape of clonal hematopoiesis KL Bolton, RN Ptashkin, T Gao, L Braunstein, SM Devlin, D Kelly, M Patel, ... Nature genetics 52 (11), 1219-1226, 2020 | 558 | 2020 |
| Ibrutinib and venetoclax for first-line treatment of CLL N Jain, M Keating, P Thompson, A Ferrajoli, J Burger, G Borthakur, ... New England Journal of Medicine 380 (22), 2095-2103, 2019 | 541 | 2019 |
| Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study K Takahashi, F Wang, H Kantarjian, D Doss, K Khanna, E Thompson, ... The lancet oncology 18 (1), 100-111, 2017 | 393 | 2017 |
| Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics K Morita, F Wang, K Jahn, T Hu, T Tanaka, Y Sasaki, J Kuipers, S Loghavi, ... Nature communications 11 (1), 5327, 2020 | 362 | 2020 |
| PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy JI Hsu, T Dayaram, A Tovy, E De Braekeleer, M Jeong, F Wang, J Zhang, ... Cell stem cell 23 (5), 700-713. e6, 2018 | 361 | 2018 |
| 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial CD DiNardo, A Maiti, CR Rausch, N Pemmaraju, K Naqvi, NG Daver, ... The Lancet Haematology 7 (10), e724-e736, 2020 | 288 | 2020 |
| Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia CD DiNardo, CA Lachowiez, K Takahashi, S Loghavi, L Xiao, T Kadia, ... Journal of Clinical Oncology 39 (25), 2768-2778, 2021 | 270 | 2021 |
| Nrf2 regulates haematopoietic stem cell function JJ Tsai, JA Dudakov, K Takahashi, JH Shieh, E Velardi, AM Holland, ... Nature cell biology 15 (3), 309-316, 2013 | 230 | 2013 |
| High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics M Pellegrino, A Sciambi, S Treusch, R Durruthy-Durruthy, K Gokhale, ... Genome research 28 (9), 1345-1352, 2018 | 222 | 2018 |
| Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia K Morita, HM Kantarjian, F Wang, Y Yan, C Bueso-Ramos, K Sasaki, ... Journal of Clinical Oncology 36 (18), 1788-1797, 2018 | 199 | 2018 |
| Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini–hyper-CVD for patients with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic … E Jabbour, F Ravandi, P Kebriaei, X Huang, NJ Short, D Thomas, ... JAMA oncology 4 (2), 230-234, 2018 | 162 | 2018 |
| Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia R Assi, H Kantarjian, NJ Short, N Daver, K Takahashi, G Garcia-Manero, ... Clinical Lymphoma Myeloma and Leukemia 17 (12), 897-901, 2017 | 158 | 2017 |
| Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms Y Sawai, K Yamao, V Bhatia, T Chiba, N Mizuno, A Sawaki, K Takahashi, ... Endoscopy 42 (12), 1077-1084, 2010 | 139 | 2010 |
| IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression CD DiNardo, E Jabbour, F Ravandi, K Takahashi, N Daver, M Routbort, ... Leukemia 30 (4), 980-984, 2016 | 135 | 2016 |
| Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study F Ravandi, R Assi, N Daver, CB Benton, T Kadia, PA Thompson, ... The Lancet Haematology 6 (9), e480-e488, 2019 | 133 | 2019 |
| Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer G Genovese, A Carugo, J Tepper, FS Robinson, L Li, M Svelto, L Nezi, ... Nature 542 (7641), 362-366, 2017 | 129 | 2017 |
| Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis P Boddu, HM Kantarjian, G Garcia-Manero, F Ravandi, S Verstovsek, ... Blood advances 1 (17), 1312-1323, 2017 | 123 | 2017 |
| Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents K Takahashi, K Patel, C Bueso-Ramos, J Zhang, C Gumbs, E Jabbour, ... Oncotarget 7 (12), 14172, 2016 | 111 | 2016 |
| Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes K Takahashi, F Wang, K Morita, Y Yan, P Hu, P Zhao, AA Zhar, CJ Wu, ... Nature communications 9 (1), 2670, 2018 | 109 | 2018 |
